Guoliang Zheng

Dr. Guoliang Zheng


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
JHJingyang He
Jingyang He
JXJingli Xu
Jingli Xu
WCWujie Chen
Wujie Chen
MCMengxuan Cao
Mengxuan Cao
JZJiaqing Zhang
Jiaqing Zhang
CHCan Hu
Can Hu
Early detection and precise preoperative staging of early gastric cancer (EGC) are critical. Therefore, this study aims to develop a deep learning model using portal venous phase CT images to accurately distinguish EGC without lymph node metastasis. This study included 3164 patients with gastric cancer (GC) who underwent radical surgery at two medical centers in China from 2006 to 2019. Moreover, 2.5D radiomic data and multi-instance learning (MIL) were novel approaches applied in this study. By basing the selection of features on 2.5D radiomic data and MIL, the ResNet101 model combined with the XGBoost model represented a satisfactory performance for diagnosing pT1N0 GC. Furthermore, the 2.5D MIL-based model demonstrated a markedly superior predictive performance compared to traditional radiomics models and clinical models. We first constructed a deep learning prediction model based on 2.5D radiomics and MIL for effectively diagnosing pT1N0 GC patients, which provides valuable information for the individualized treatment selection.

10 January 2023 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
GZGuoliang Zheng
Guoliang Zheng
GZGuo-Jun Zhang
Guo-Jun Zhang
YZYan Zhao
Yan Zhao
ZZZhi-Chao Zheng
Zhi-Chao Zheng
An abnormality in the regulation of adenosine deaminase acting on RNA (ADAR) enzymes, which catalyzed adenosine-to-inosine (A-to-I) RNA editing, was closely associated with the highly aggressive biologic behavior and poor prognosis in many malignancies. In the present study, we aimed to investigate the relationship among transcript factors-microRNAs regulatory network, immune environment, and ADAR gene in colorectal carcinoma (CRC). The association among the expression levels of ADAR mRNA and copy number variation, methylation, and mutation status were comprehensively analyzed using cBioPortal, Wanderer, and UALCAN databases in CRC datasets. ADAR-transcript factors (TFs) and ADAR-miRNA regulation networks were constructed by Cistrome Cancer and miRWalk2.0, respectively. The full network and subnetworks for ADAR coexpression genes were constructed using the STRING database and visualized by the MCODE module of the Cytoscape app. The relationship between ADAR mRNA expression and the abundance of infiltrating immune cells in CRC patients was explored by the Tumor Immune Estimation Resource, CIBERSORT, and single-gene gene set enrichment analysis (GSEA). ADAR mRNA was elevated and was a cancer essential gene in CRC. ADAR mRNA and transcripts P110 were significantly elevated in CRC compared to normal controls. Low-level methylation in the promoter region and high copy number amplification of ADAR were responsible for high levels of ADAR mRNA expression. ADAR coexpression genes were mainly involved in immunoregulation, especially T-lymphocyte activation. Hub genes, including CD2, CD274, and FASLG, were also significantly upregulated in the ADAR-high group compared to the control group. Besides, M1 macrophages were enriched in the ADAR-high group compared to the control group. This study demonstrated that ADAR, a new essential gene, was involved in the immune regulator and was a novel immune treatment target in CRC.

22 August 2023 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HZHuawei Zhu
Huawei Zhu
YXYanbo Xu
Yanbo Xu
JXJun Xia
Jun Xia
XGXu Guo
Xu Guo
YFYujie Fang
Yujie Fang
YLYubo Liu
Yubo Liu

1 January 2026 in The Innovation Oncology
Verified
Journal Article
Open access
PDF file
XXXin Xin
Xin Xin
YLYan Li
Yan Li
GZGuoliang Zheng
Guoliang Zheng

4 September 2026 in BMC Medicine
Verified
Journal Article
Open access
PDF file
XLXu Liu
Xu Liu
PJPeng Jin
Peng Jin
PWPeng Wang
Peng Wang
XSXinxin Shao
Xinxin Shao
HWHaikuo Wang
Haikuo Wang
YTYantao Tian
Yantao Tian
The benefit of adjuvant chemotherapy (ACT) for patients with gastric cancer (GC) after first-line neoadjuvant chemotherapy (NACT) is debated. This study de